RPRX Royalty Pharma plc - Class A Earnings and EPS analysis

?
Relative Growth: Rel. Growth: 59
Relative Strength: Rel. Strength: 83
Relative Valuation: Rel. Valuation: 19
Relative Profitability: Rel. Profitability: 77

EPS in 2026 (TTM): $1.88

Last Report Period Date: Jun 30, 2026

As of August 2026, according to Royalty Pharma plc - Class A's latest financial report, the company's current EPS (TTM) is $1.88. In 2025, the company recorded an earnings per share (EPS) of $1.79, which represents a decrease compared to its EPS of $1.92 in 2024. Royalty Pharma plc - Class A's earnings per share for the quarterly report ending on Jun 30, 2026 was $0.04.

RPRX earnings history

Historical annual and quarterly earnings per share (EPS) data for Royalty Pharma plc - Class A
EPS (TTM)
$1.88
EPS Growth YoY (Quarterly)
-50%
EPS (Quarterly)
$0.04
EPS Growth (Quarterly)
-94%

The annual EPS in 2025 was $1.79, a decrease of 6.8% from $1.92 in 2024. For the quarter ending Jun 30, 2026, the EPS was $0.04, showing a 50% decrease from the same quarter last year. The trailing twelve months (TTM) EPS as of June 2026 is $1.88. In 2024, the annual EPS was $1.92, showing a decrease of 24.4% from 2023.

RPRX EPS vs price chart

RPRX EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
-50%
EPS growth YoY
-6.8%
EPS growth 3Y avg
161.6%
EPS growth 5Y avg
6.3%

Royalty Pharma plc - Class A has recorded a decrease in EPS of 50% over the last 12 months (YoY, quarterly). Looking at a longer timeframe, the company recorded an average EPS growth rate of 161.6% per year over the past 3 years. Royalty Pharma plc - Class A had an average annual EPS growth rate of 6.3% over the last 5 years.

RPRX Earnings Waterfall

Breakdown of revenue, profit and net income for Royalty Pharma plc - Class A

RPRX Earnings vs Peers

What are the earnings of RPRX compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
ANIP Ani Pharmaceuticals Inc 15.6 436.5% N/A N/A
RPRX Royalty Pharma plc - Class A 32.61 -6.8% 161.6% 6.3%
ABT Abbott Laboratories 37.63 -51.4% -1.8% 8.2%
LLY Lilly(Eli) & Company 42.07 95.6% 49.2% 27.5%

All data is based on quarterly TTM periods, unless otherwise specified.